Skip to main content
Bioceltix S.A. logo

Bioceltix S.A. — Investor Relations & Filings

Ticker · BCX ISIN · PLBCLTX00019 LEI · 259400QZD5JYK8SLZU51 WAR Manufacturing
Open in API
Filings indexed 270 across all filing types
Latest filing 2022-12-06 Capital/Financing Update
Country PL Poland
Listing WAR BCX

About Bioceltix S.A.

https://bioceltix.com/en/

Bioceltix S.A. is a biopharmaceutical company that develops stem cell-based medicinal products for veterinary use. The company focuses on creating therapies that utilize Mesenchymal Stem Cells (MSCs) as the active pharmaceutical ingredient. Its product pipeline is aimed at treating immunological and inflammatory conditions in companion animals, including dogs, cats, and horses. A key area of development includes treatments for conditions such as atopic dermatitis in dogs and degenerative joint disease.

Recent filings

Filing Released Lang Actions
Dojście do skutku emisji akcji serii J, dookreślenie wysokości kapitału zakładowego oraz podsumowanie subskrypcji akcji serii J - Content (PL)
Capital/Financing Update Classification · 1% confidence The document text is a formal announcement by the Management Board ('Zarząd') of Bioceltix S.A. detailing the completion of a private placement ('subskrypcja prywatna') of new shares (Series J) and the resulting increase in the share capital ('podwyższenia kapitału zakładowego'). It provides specific figures regarding the number of shares issued (152,143), the issue price (31.00 PLN), total proceeds (4,716,433 PLN), and associated issuance costs. It also includes the updated structure of the share capital in the company's Articles of Association ('Statut'). This content directly relates to fundraising, financing activities, and capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-12-06 Polish
Powiadomienie o transakcji na akcjach Emitenta dokonanej przez osobę pełniącą obowiązki zarządcze
Director's Dealing Classification · 1% confidence The document is titled "Powiadomienie o transakcji/transakcjach*, o którym mowa w art. 19 ust. 1 rozporządzenia MAR" (Notification of transaction(s) referred to in Article 19(1) of the MAR Regulation). Article 19 of the Market Abuse Regulation (MAR) specifically deals with notifications of transactions conducted by persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. The content details a transaction (Subscription/Subskrypcja) involving shares (Akcje) by a Member of the Management Board (Członek Zarządu) named Paweł Wielgus. This directly corresponds to the definition of Director's Dealing (insider trades by executives).
2022-12-02 Polish
Powiadomienie o transakcji na akcjach Emitenta dokonanej przez osobę pełniącą obowiązki zarządcze - Content (PL)
Director's Dealing Classification · 1% confidence The document text is very short (373 characters) and explicitly states that the management received a notification regarding a transaction concerning the Issuer's shares (akcji Emitenta) from a Board Member (Pawła Wielgusa jako Członka Zarządu Emitenta) on December 2, 2022. It concludes by stating that the notification is an attachment to the current report ('załącznik do niniejszego raportu bieżącego'). This structure—a brief announcement referencing an attached document detailing insider transactions—strongly suggests a Director's Dealing report (DIRS) being disclosed via a regulatory filing mechanism. Since the text itself is the announcement of the transaction details (the notification), and not the full annual/quarterly report, DIRS is the most specific fit for the content described (transaction by a director).
2022-12-02 Polish
Ustalenie ceny emisyjnej akcji serii J Bioceltix S.A. - Content (PL)
Share Issue/Capital Change Classification · 1% confidence The document text, written in Polish, discusses the Management Board ('Zarząd') of Bioceltix S.A. resolving to set the issue price ('cena emisyjna') for a new series of ordinary shares ('akcji zwykłych na okaziciela serii J'). This action directly relates to the issuance of new shares and changes in the company's capital structure. This aligns perfectly with the definition of 'Share Issue/Capital Change' (Code: SHA). The document is a formal announcement regarding the pricing of a new share issue.
2022-11-23 Polish
Status realizacji badania pilotażowego ukierunkowanego na potwierdzenie skuteczności produktu BCX-CM-AD przeznaczonego do leczenia atopowego zapalenia skóry u psów - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a formal announcement from the Management Board ("Zarząd") of Bioceltix S.A. regarding the current status of a commissioned veterinary clinical trial for a product (BCX-CM-AD). It details the progress, patient numbers, methodology (comparison to a control group), and preliminary positive assessment of the results. This type of update, which provides ongoing operational and development news that is material to the company's prospects but is not a full financial report (like 10-K or IR), typically falls under general regulatory announcements or investor updates. Since it is an update on a specific development (clinical trial status) and not a standard financial release (ER, IR) or a management discussion (MDA), and it is a formal report to the market, it best fits the 'Regulatory Filings' (RNS) category as a general, material disclosure, or potentially an 'LTR' if the trial itself was regulatory mandated, but RNS is the broader fit for material operational updates not covered elsewhere. Given the context of providing ongoing operational progress updates, RNS is the most appropriate general regulatory disclosure category.
2022-11-16 Polish
Raport kwartalny Bioceltix S.A. za III kwartał 2022 r. zawierający informację dodatkową do Sprawozdania Finansowego za okres 01.07.2022 - 30.09.2022.
Interim / Quarterly Report Classification · 1% confidence The document is a 'Raport Kwartalny' (Quarterly Report) for Bioceltix S.A. for the third quarter of 2022. It contains comprehensive financial statements, including balance sheets, income statements, cash flow statements, and management commentary on business activities. It is not a mere announcement or certification, but the full interim report itself, fitting the definition of an Interim/Quarterly Report (IR). Q3 2022
2022-11-07 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.